Table 1.
The patient characteristics for 297 patients with locally advanced rectum cancer patients
| Clinical factors | % | |
|---|---|---|
| Gender (number) | ||
| Male | 207 | 69.7 |
| Female | 90 | 30.3 |
| Median age (year, range) | 56 (15-80) | |
| Median Pre-CEA level (ng/ml, range) | 4.5 (0.2-249.6) | |
| Median Pre-Hb (g/L, range)$ | 130 (64-170) | |
| Distance anal verge (cm, range) | 5 (1-15) | |
| Methods clinical stage (number) | ||
| ERUS | 274 | 92.3 |
| CT | 189 | 63.6 |
| MRI | 87 | 29.3 |
| Clinical T (number) | ||
| T1 | 4 | 1.3 |
| T2 | 8 | 2.7 |
| T3 | 110 | 37 |
| T4 | 175 | 58.9 |
| Clinical N (number) | ||
| N0 | 92 | 31.0 |
| N+ | 205 | 69.0 |
| Histologic grade (number) | ||
| G1 | 21 | 7.1 |
| G2 | 238 | 80.1 |
| G3 | 38 | 12.8 |
| Median preoperative radiotherapy dose (Gy, range) | 46 (30-50) | |
| Prechemotherapy (number) | ||
| FOLFOX | 47 | 16.1 |
| XELOX | 229 | 78.4 |
| others | 16 | 5.5 |
| Interval between completion of neo-CRT and surgery (day, range) | 45 (20-142) | |
| Surgery (number) | ||
| Miles | 129 | 43.4 |
| Dixon | 159 | 53.5 |
| Hartmann | 9 | 3 |
| Median lymph node from surgery (number, range) | 5 (0-27) |
$: Pre-Hb: pre-treatment level of hemoglobin